Operating Income (Loss) in USD of Achilles Therapeutics plc from 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Achilles Therapeutics plc quarterly/annual Operating Income (Loss) history and change rate from 2019 to Q2 2024.
  • Achilles Therapeutics plc Operating Income (Loss) for the quarter ending 30 Jun 2024 was -$17.8M, a 1.62% increase year-over-year.
  • Achilles Therapeutics plc annual Operating Income (Loss) for 2023 was -$75.3M, a 3.99% increase from 2022.
  • Achilles Therapeutics plc annual Operating Income (Loss) for 2022 was -$78.4M, a 22.1% decline from 2021.
  • Achilles Therapeutics plc annual Operating Income (Loss) for 2021 was -$64.2M, a 90.3% decline from 2020.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Achilles Therapeutics plc Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$17.8M +$293K +1.62% 01 Apr 2024 30 Jun 2024 6-K 14 Aug 2024
Q2 2023 -$18.1M +$2.45M +11.9% 01 Apr 2023 30 Jun 2023 6-K 14 Aug 2024
Q2 2022 -$20.5M 01 Apr 2022 30 Jun 2022 6-K 04 Aug 2023

Achilles Therapeutics plc Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$75.3M +$3.13M +3.99% 01 Jan 2023 31 Dec 2023 20-F 04 Apr 2024
2022 -$78.4M -$14.2M -22.1% 01 Jan 2022 31 Dec 2022 20-F 04 Apr 2024
2021 -$64.2M -$30.5M -90.3% 01 Jan 2021 31 Dec 2021 20-F 04 Apr 2024
2020 -$33.7M -$20M -145% 01 Jan 2020 31 Dec 2020 20-F 07 Mar 2023
2019 -$13.8M 01 Jan 2019 31 Dec 2019 20-F 01 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.